Skip to main content

Lung cancer

Lung cancer

24-06-2019 | Oncology | News | Article

Adding chemotherapy to gefitinib improves EGFR-mutated NSCLC outcomes

Supplementing the EGFR–tyrosine kinase inhibitor gefitinib with pemetrexed and carboplatin doubles progression-free survival in patients with advanced, chemotherapy-naïve non-small-cell lung cancer harboring activating EGFR mutations, according to phase III results.

21-06-2019 | Oncology | News | Article

Neoadjuvant immunotherapy shows promise for resectable NSCLC

Neoadjuvant immunotherapy produces encouraging major pathologic response rates among patients with resectable non-small-cell lung cancer, show data presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

20-06-2019 | Oncology | News | Article

Maintenance bevacizumab–pemetrexed improves PFS of nonsquamous NSCLC patients

Two studies presented at the 2019 ASCO Annual Meeting show a significant progression-free survival, but not overall survival, benefit with the addition of pemetrexed to bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer.

19-06-2019 | Oncology | News | Article

No survival boost for advanced NSCLC with metformin

Metformin does not improve progression-free survival for patients without diabetes who require chemoradiotherapy for stage IIIA or IIIB non-small-cell lung cancer, suggests research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

18-06-2019 | Oncology | News | Article

Broadening clinical trial inclusion criteria doubles number of eligible NSCLC patients

Using expanded criteria for clinical trial inclusion could lead to nearly twice as many patients with advanced non-small-cell lung cancer being eligible for participation compared with traditional criteria, participants at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, heard.

14-06-2019 | Oncology | News | Article

TAK-788 shows activity against NSCLC with EGFR exon 20 insertions

The EGFR and HER2 inhibitor TAK-788 has antitumor activity against non-small-cell lung cancer with EGFR exon 20 insertions, according to phase I/II findings reported at the 2019 ASCO Annual Meeting.

13-06-2019 | Oncology | News | Article

BLU-667 active against RET fusion-positive advanced NSCLC

Phase I data indicate that the selective RET inhibitor BLU-667 elicits durable responses and is well tolerated by individuals with advanced non-small-cell lung cancer harboring a RET fusion.

11-06-2019 | Oncology | News | Article

RELAY: Ramucirumab–erlotinib a potential first-line option for EGFR-mutated NSCLC

Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

07-06-2019 | Oncology | News | Article

Prolonged survival possible with pembrolizumab in advanced NSCLC

Updated results from the phase Ib KEYNOTE-001 trial suggest that some individuals with advanced non-small-cell lung cancer can achieve long-term survival with pembrolizumab monotherapy.

07-06-2019 | Oncology | News | Article

Lurbinectedin shows potential for second-line SCLC treatment

Lurbinectedin monotherapy is active in the second-line treatment of both platinum-sensitive and -resistant small-cell lung cancer, according to phase II results presented at the 2019 ASCO Annual Meeting.

05-06-2019 | Oncology | Main feed | News

EGFR–cMET bispecific antibody shows efficacy in NSCLC patients with high unmet needs

Preliminary findings for a first-in-human study of JNJ-372 – a bispecific IgG antibody targeting both the EGFR and cMET receptors – have been reported at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

03-06-2019 | Oncology | Main feed | News

HER3-targeted antibody–drug conjugate shows promise for TKI-resistant NSCLC

Early results suggest that a novel antibody–drug conjugate directed against HER3 has antitumor activity and manageable safety in patients with EGFR-mutated metastatic non-small-cell lung cancer and acquired resistance to EGFR–tyrosine kinase inhibitors.

29-05-2019 | Oncology | News | Article

First-line atezolizumab–chemotherapy an option for nonmutated metastatic NSCLC

Patients with treatment-naïve, nonmutated, nonsquamous, advanced non-small-cell lung cancer derive a significant survival benefit from the addition of the PD-L1 inhibitor atezolizumab to chemotherapy, indicate phase III trial findings.

24-05-2019 | Oncology | News | Article

Twice-daily radiotherapy may increase brain metastasis risk in SCLC

Marginal survival gains among patients with small-cell lung cancer who receive twice- versus once-daily thoracic radiotherapy plus prophylactic cranial irradiation occur at the cost of an increased risk for brain metastases, research shows.

21-05-2019 | Oncology | News | Article

No benefit with nintedanib in advanced malignant pleural mesothelioma

Adding nintedanib to pemetrexed plus cisplatin does not improve progression-free survival for patients with advanced malignant pleural mesothelioma, say researchers who conducted a phase III trial on the basis of earlier positive findings.

17-05-2019 | Oncology | News | Article

CTCs prognostic in limited-stage SCLC

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

16-05-2019 | Oncology | News | Article

Immunotherapy response differs by EFGR mutation subtype

The response to treatment with immune checkpoint inhibitors varies according to EGFR mutant subtype in patients with non-small-cell lung cancer, US researchers report.

14-05-2019 | Oncology | News | Article

Whole-body MRI staging quicker and cheaper than standard pathways in NSCLC

The Streamline L trial has found that in patients with newly diagnosed non-small-cell lung cancer, a staging pathway using whole-body magnetic resonance imaging has similar accuracy but a shorter time to complete staging and lower mean per-patient costs versus standard pathways.

13-05-2019 | Oncology | News | Article

Local consolidative therapy improves oligometastatic NSCLC survival

Patients with stage IV non-small-cell lung cancer and no more than three metastases derive an overall survival benefit from aggressive local consolidative therapy, suggest trial results.

07-05-2019 | Oncology | News | Article

Immunotherapy-related AEs reviewed, underlying mechanism postulated

Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.

Image Credits